Home › Compare › SKUYF vs ABBV
SKUYF yields 4.96% · ABBV yields 3.06%● Live data
📍 ABBV pulled ahead of the other in Year 1
Combined, SKUYF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of SKUYF + ABBV for your $10,000?
Sansei Technologies, Inc. plans, designs, manufactures, installs, repairs, and maintains amusement rides, stage equipment, elevators, and other designed equipment in Japan and internationally. The company's amusement rides include dark rides, mini-roller coasters, family rides and others, carousel type rides, jet-roller coasters, and flume rides. It also provides stage equipment, such as floor mechanisms comprising elevators for stage traps, sliding stages and stage wagons, inclined floors, circular-type stages, etc. In addition, the company offers rigging systems for raising and lowering the scenery, lighting, sound and screen equipment, stage curtains, acoustic panels, etc.; acoustic equipment; control systems; and stage equipment for small halls, adaptable stages, event halls, sports halls, and studios. Further, it provides property management and logistics services; operates and manages amusement facilities; and rents electric and mechanical equipment for TV programs, concerts, stages, events, etc. The company was formerly known as Sansei Yusoki Co., Ltd. and changed its name to Sansei Technologies, Inc. in January 2014. Sansei Technologies, Inc. was incorporated in 1951 and is headquartered in Osaka, Japan.
Full SKUYF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.